Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome

• Amrita Goyal, MD,
• Damodaran Narayanan, MBBS, PhD,
• Waihay Wong, MD, PhD,
• Alvaro C. Laga, MD,
• Nathan T. Connell, MD, MPH,
• Susan Y. Ritter, MD, PhD,
• Gabriela Cobos, MD

Affiliations

Amrita Goyal, MD

Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts; Department of Dermatology, University of Minnesota, Minneapolis, Minnesota; Correspondence to: Amrita Goyal, MD, Department of Dermatology, University of Minnesota, Twin Cities, 516 Delaware St, SE, Minneapolis, MN 55401.

Damodaran Narayanan, MBBS, PhD

Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts

Waihay Wong, MD, PhD

Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts

Alvaro C. Laga, MD

Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts

Nathan T. Connell, MD, MPH

Hematology Division, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts

Susan Y. Ritter, MD, PhD

Department of Rheumatology, Brigham and Women’s Hospital, Boston, Massachusetts

Gabriela Cobos, MD

Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts